3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
3
Head & Neck
2
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Lung Neoplasms
3
Thyroid Neoplasms
2
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Medullary
2
Carcinoma, Bronchogenic
2
Carcinoma
2
Adenocarcinoma
2
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Glandular and Epithelial
1
Multiple Endocrine Neoplasia Type 2a
1
Locally Advanced Thyroid Gland Carcinoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Interventions
Carboplatin
339
Cisplatin
238
Paclitaxel
203
Radiotherapy
194
Pemetrexed
187
Docetaxel
169
Gemcitabine
157
pembrolizumab
140
Erlotinib Hydrochloride
107
Etoposide
98
Magnetic Resonance Spectroscopy
92
Bevacizumab
91
Specimen Handling
76
Nivolumab
73
Radiosurgery
71
durvalumab
69
Vinorelbine
54
osimertinib
53
Gefitinib
49
Drug Therapy
49
Irinotecan
42
atezolizumab
41
Topotecan
39
Radiation
39
Biopsy
39
Cyclophosphamide
38
Standard of Care
37
Cetuximab
35
Blood Specimen Collection
33
Taxes
32
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Lung Neoplasms
×
pralsetinib
×
Clear all
NCT06563999
2026-04-21
NUMER
Sun Yat-sen University
Phase 2
Recruiting
120 enrolled
NCT04222972
2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3
Terminated
223 enrolled
18 charts
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA